Cargando…

390 A Mixed Methods Review of Endpoint Measures Utilized in Adult ADHD Medication Clinical Trial Design

OBJECTIVES/GOALS: To evaluate the clinical trial designs of stimulant medications approved for the treatment of adult Attention-Deficit/Hyperactivity Disorder (ADHD) and identify discrepancies between safety and efficacy outcome measure criteria. METHODS/STUDY POPULATION: There are 24 stimulants cur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Claire, Church, Terry David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Regulatory Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129487/ http://dx.doi.org/10.1017/cts.2023.425

Ejemplares similares

95347 Examining the Impact of the BPCA: Promoting Pediatric Inclusion in Clinical Trials and Pediatric-Specific Drug Information
por: Ly, Annie, et al.
Publicado: (2021)

397 Regulations and Marketing of Energy Drinks in the United States: A Survey of University Student Beliefs about Caffeine Consumption
por: Chung, Christian, et al.
Publicado: (2023)

393 Disposable Electronic Nicotine Delivery Systems (ENDS) and Underage Nicotine Addiction–A Survey of College Students
por: Riggs, Griffin, et al.
Publicado: (2023)

Registration of Medical Devices
por: George, Bobby
Publicado: (2010)

Integration of data across toxicity endpoints for improved safety assessment of chemicals: the example of carcinogenicity assessment
por: Madia, Federica, et al.
Publicado: (2021)

Drug Lag and Key Regulatory Barriers in the Emerging Markets
por: Wileman, Harriet, et al.
Publicado: (2010)

Regulations and guidelines governing stem cell based products: Clinical considerations
por: George, Bobby
Publicado: (2011)

Regulatory Considerations for Biosimilars
por: Nellore, Ranjani
Publicado: (2010)

Implications of ICH-E5: Assessment of drug's sensitivity to ethnic factors and necessity of a bridging study for global drug development
por: Gupta, Sandeep Kumar
Publicado: (2011)

Regulatory requirements for marketing fixed dose combinations
por: Jayasheel, B. G.
Publicado: (2010)

Injury and death in clinical trials and compensation: Rule 122 DAB
por: Ghooi, Ravindra. B.
Publicado: (2013)

Key points of technical review for the registration of SARS-CoV-2 antigen/antibody tests
por: Li, Hongran, et al.
Publicado: (2021)

China NMPA perspective on clinical evaluation of SARS-CoV-2 antibody test reagents in the process of emergency approval
por: Lv, Yunfeng, et al.
Publicado: (2020)

Key points of technical review for the registration of SARS-CoV-2 nucleic acid tests in China
por: Li, Hongran, et al.
Publicado: (2021)

China's NMPA perspective on the clinical performance of SARS-CoV-2 antigen test reagents
por: Lv, Yunfeng, et al.
Publicado: (2022)

Good Clinical Practice Training: Identifying Key Elements and Strategies for Increasing Training Efficiency
por: Arango, Jaime, et al.
Publicado: (2016)

Translating New Science Into the Drug Review Process: The US FDA’s Division of Applied Regulatory Science
por: Rouse, Rodney, et al.
Publicado: (2017)

Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable
por: Dreyer, Nancy A.
Publicado: (2018)

Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval
por: Harada, Kenji, et al.
Publicado: (2019)

4505 Implementation of Real-World Data and Real-World Evidence in Clinical Studies
por: Pham, Jessica, et al.
Publicado: (2020)

4186 Single IRB and the CTSI: Liaison Model for the IRB Reliance Process
por: Caldwell, Christine Sego, et al.
Publicado: (2020)

4349 Survey of Regulatory Reforms to Address Comprehension of Clinical Trial Results
por: Kirkland, Matthieu, et al.
Publicado: (2020)

4500 Providing a System for Practical Monitoring Training for Clinical Trials within Academic Institutions
por: Chandramohan, Advaita, et al.
Publicado: (2020)

81007 Training Biomedical Engineers in Regulatory Science: Critical Role of Experts from Industry and FDA
por: Lottes, Aaron E., et al.
Publicado: (2021)

399 The development of a digital game to prevent suicide in youth who misuse substances
por: Fernandes, Claudia-Santi F., et al.
Publicado: (2023)

391 An Investigation on the Activity of Repurposing Already Marketed Drugs for New Indications from 2015 to 2021.
por: Wu, Wenchao, et al.
Publicado: (2023)

395 Hindering Generic Antiretroviral Treatment Competition for Human Immunodeficiency Virus: Anti-Competitive Agreements and HIV Disease Management Concerns
por: Crovetto, Arianna
Publicado: (2023)

394 Examining the Landscape of Clinical Trials Targeting Alcohol or Opioid Use Among Homeless Individuals
por: Baltazar, Bruno, et al.
Publicado: (2023)

392 Basic Researcher Interviews to iDentify Gaps to Enabling Translation (BRIDGE Translation)
por: Thepmankorn, Parisorn, et al.
Publicado: (2023)

398 Researcher Perceived Barriers in Translational Research
por: Mukherjee, Sunaina, et al.
Publicado: (2023)

396 Quantitative Analysis of FDA Warning Letters Related to the Use of Social Media Sites in Product Misbranding for the Treatment, Prevention, or Diagnosis of COVID-19
por: Ajaj, Mahmoud, et al.
Publicado: (2023)

400 Exploring the Diversity of Expanded Access Patients at Michigan Medicine
por: Gravelin, Misty, et al.
Publicado: (2023)

Regulatory Issues: PMDA – Review of Sakigake Designation Products: Oncolytic Virus Therapy with Delytact Injection (Teserpaturev) for Malignant Glioma
por: Maruyama, Yoshiaki, et al.
Publicado: (2023)

Modernizing persistence–bioaccumulation–toxicity (PBT) assessment with high throughput animal-free methods
por: Escher, Beate I., et al.
Publicado: (2023)

Species differences and human relevance of the toxicity of 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors and a new approach method in vitro for investigation
por: Botham, Jane, et al.
Publicado: (2023)

Standardisation of defined approaches for skin sensitisation testing to support regulatory use and international adoption: position of the International Cooperation on Alternative Test Methods
por: Casati, S., et al.
Publicado: (2017)

The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors
por: Tesileanu, C Mircea S, et al.
Publicado: (2023)

Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model
por: Tonnelier, Arnaud, et al.
Publicado: (2011)

Indian Regulatory Update: Jan-May 2014
por: Suvarnapathaki, Kedar
Publicado: (2014)

Sensory irritation as a basis for setting occupational exposure limits
por: Brüning, Thomas, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_71a923bg82b5v5aajs4311p3vr